Clinical Trials Logo

Clinical Trial Summary

Subjects will receive multiple sub-doses over a 4-hour period to deliver a total overall dose of 1E11. Evaluations of immunogenicity, safety, and tolerability will be evaluated. The active period consists of data collection at Day 1, Day 8, and Day 29. Safety follow-up continues by phone screen at Day 180 and Day 365.


Clinical Trial Description

Primary Objective - To determine the immunogenicity of the VXA-G1.1-NN oral vaccine administered via multiple sub-doses over a 4-hour period to deliver a total dose of 1E11 IU ±0.5 log Secondary Objectives - To determine the safety and tolerability of the VXA-G1.1-NN oral vaccine administered via multiple sub-doses over a 4-hour period to deliver a total dose of 1E11 IU ±0.5 log This is an open-label study in healthy adult participants aged 18-55 years old. The study will enroll 8 subjects to a single treatment cohort, all of whom will receive a single 1E11 IU± 0.5 log at Day 1. This dose will be administered in a step wise manner over 4 hours with 1/3 of the dose administered at T=0, 1/3 of the dose administered at T= 2 hours and 1/3 of the dose administered at T=4 hours. The study will include a Screening Period, Active Period (Day 1 to Day 29, 4 weeks post vaccination) and a Safety Follow-up Period through 12 months post vaccination (Day 365). In addition, participants will be contacted by phone during the Safety Follow-up Period to assess for Serious Adverse Events (SAEs), AEs of Special Interest (AESIs) and New Onset of Chronic Illness (NOCIs). After signing an informed consent, participants will undergo screening assessments to determine study eligibility within a 30-day screening period. Eligible participants will be enrolled and receive their first dose of study vaccine on Day 1. During the Active Period, participants will record any potential solicited symptoms of reactogenicity daily for 1 week post study vaccination. Participants will return to the site as specified in the Schedule of Activities to have safety assessments and samples collected for evaluation of immunogenicity. Approximately 8 subjects will be vaccinated in the active phase. The following study visits and remote contacts will be conducted during the study: Active Period: - Screening Period (Days -30 to -1) - Day 1 Visit (Baseline assessments, vaccination, sample collection) - Day 8 Visit (Safety assessments, sample collection) - Day 29 End of Active Period; (Safety assessments, sample collection) Safety Follow-Up Period: - Day 180 (follow-up phone call for safety) - Day 365 (follow-up phone call for safety): Study completion ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05213728
Study type Interventional
Source Vaxart
Contact
Status Completed
Phase Phase 1
Start date January 24, 2022
Completion date February 24, 2022

See also
  Status Clinical Trial Phase
Terminated NCT02371538 - Human Breastmilk in Young Children With Norovirus Infection of the Gut N/A
Completed NCT04188691 - A Clinical Trial to Evaluate the Safety and Immunogenicity of Norovirus Bivalent Vaccine Phase 1
Recruiting NCT04941261 - Clinical Trial to Evaluate the Recombinant Norovirus Bivalent (GI. 1 / GII. 4) Vaccine (Hansenula Polymorpha) Phase 2
Recruiting NCT05212168 - Norovirus Challenge Study Phase 1/Phase 2
Completed NCT01435811 - Dose Range Evaluation of Norovirus Challenge Pool (GII.4, CIN-1) Phase 1
Completed NCT04875676 - Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines Phase 1/Phase 2
Completed NCT04854746 - Ph 1b: Safety & Immunogenicity of Ad5 Based Oral Norovirus Vaccine Phase 1